49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00000419 (ClinicalTrials.gov) | April 1996 | 3/11/1999 | Safety of Estrogens in Lupus: Hormone Replacement Therapy | Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Hormone Replacement Therapy | Systemic Lupus Erythematosus | Drug: Premarin and Provera | New York University School of Medicine | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Office of Research on Women's Health (ORWH) | Terminated | 18 Years | 85 Years | Female | 350 | Phase 3 | United States |